GeoVax Labs, Inc. - Warrants (OQ:GOVXW)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Apr 04, 2024 12:30 pm ET

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on...

Mar 28, 2024 09:00 am ET

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on...

Mar 12, 2024 09:00 am ET

GeoVax to Present at the 36th Annual Roth Conference

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual...

Mar 06, 2024 09:00 am ET

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken...

Feb 29, 2024 04:00 pm ET

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year...

Feb 22, 2024 09:00 am ET

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday,...

Feb 19, 2024 09:00 am ET

GeoVax to Present at the 2024 BIO CEO & Investor Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO &...

Feb 13, 2024 09:00 am ET

GeoVax Announces Multiple Patent Issuances and Allowances

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company’s...

Feb 06, 2024 09:00 am ET

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced positive initial safety and immune response findings from its Phase 2...

Jan 29, 2024 09:00 am ET

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has approved a reverse stock split...

Jan 08, 2024 09:00 am ET

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company’s...

Jan 04, 2024 09:00 am ET

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study...

Jan 03, 2024 09:00 am ET

GeoVax Announces Issuance of Malaria Vaccine Patent

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611...

Dec 27, 2023 09:00 am ET

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech...

Dec 19, 2023 09:00 am ET

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological Materials...

Nov 30, 2023 04:30 pm ET

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies of its vaccine...

Nov 29, 2023 09:00 am ET

GeoVax to Participate in Upcoming December Investor Events

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its senior management will participate in two upcoming investor...

Nov 28, 2023 09:00 am ET

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from the active development program for its...

Nov 14, 2023 09:00 am ET

Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a...

Nov 08, 2023 04:00 pm ET

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter ended September 30, 2023 and...

Oct 31, 2023 09:00 am ET

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

Oct 30, 2023 09:00 am ET

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical...

Oct 25, 2023 09:00 am ET

GeoVax to Participate in Upcoming November Investor and Industry Events

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific...

Oct 24, 2023 09:00 am ET

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced an update on key strategic initiatives. “The third quarter marked...

Oct 09, 2023 09:00 am ET

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of...

Oct 05, 2023 09:00 am ET

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance...

Sep 27, 2023 09:00 am ET

GeoVax to Participate in Upcoming October Investor and Industry Events

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chairman and Chief Executive Officer, will participate in...

Sep 26, 2023 09:00 am ET

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, and ProBioGen announce the signing of a landmark commercial license agreement for...

Sep 20, 2023 09:00 am ET

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of preclinical vaccine efficacy data for GEO-CM02, a...

Sep 19, 2023 09:00 am ET

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of data from the ongoing Phase 2 trial of its...

Sep 12, 2023 09:00 am ET

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview...

Sep 11, 2023 09:00 am ET

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has met the enrollment target for its Phase 2 clinical trial...

Aug 31, 2023 09:00 am ET

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will present a company overview and host investor meetings during...

Aug 29, 2023 09:00 am ET

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the Emerging Growth...

Aug 28, 2023 09:00 am ET

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance...

Aug 10, 2023 09:00 am ET

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months via NewMediaWire — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers...

Aug 09, 2023 04:00 pm ET

GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update

via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the quarter ended June 30, 2023, and recent...

Jul 26, 2023 09:00 am ET

GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report second quarter 2023 financial results on...

Jul 24, 2023 09:00 am ET

GeoVax Announces Issuance of Ebola Vaccine Patent

via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,701,418...

Jul 20, 2023 09:00 am ET

GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the start of an investigator-initiated clinical trial (ClinicalTrials.gov...

Jul 10, 2023 09:00 am ET

GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of Phase 1/2 clinical trial data for GeoVax’s gene...

Jun 28, 2023 09:00 am ET

GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that an abstract regarding GeoVax’s gene therapy candidate, Gedeptin®, has...

Jun 27, 2023 10:15 am ET

GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights

via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of an article titled, “MVA-Vectored Universal...

May 31, 2023 09:00 am ET

GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced it has executed a Master Services Agreement (MSA) with Advanced Bioscience...

May 25, 2023 09:00 am ET

GeoVax to Participate in Upcoming Industry Meetings

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chief Medical Officer, Kelly T. McKee, M.D., will participate in the...

May 24, 2023 08:00 am ET

GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of updates on the development of its next-generation...

May 15, 2023 09:00 am ET

GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented during two upcoming scientific meetings,...

May 09, 2023 09:00 am ET

GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ Virtual...

May 04, 2023 04:00 pm ET

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

via NewMediaWire– GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its financial results for the three months ended March 31, 2023, and recent...

Apr 26, 2023 09:00 am ET

GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on...

Apr 25, 2023 09:00 am ET

GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial results on...

Apr 17, 2023 09:00 am ET

GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the expansion of its rights under its exclusive license agreement with...

Apr 06, 2023 10:00 am ET

GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, presented an update on the development of its SARS-CoV-2 vaccine, GEO-CM04S1, including...

Apr 05, 2023 01:30 pm ET

GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of encouraging data from recent nonhuman primate studies...

Mar 30, 2023 11:00 am ET

GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented in two presentations during the upcoming 23rd...

Mar 23, 2023 04:00 pm ET

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year...

Mar 15, 2023 09:00 am ET

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against solid tumor cancers and infectious diseases, today congratulates its colleague and collaborator, Don Diamond, Ph.D. for...

Mar 09, 2023 09:00 am ET

GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday,...

Mar 06, 2023 09:00 am ET

GeoVax to Participate at the 35th Annual Roth Conference

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will discuss the company’s...

Feb 27, 2023 09:00 am ET

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of results from a clinical study of a combinational HIV...

Feb 15, 2023 09:00 am ET

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organization, today...

Feb 08, 2023 09:00 am ET

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced significant progress in developing a high-yield, high-capacity, continuous...

Feb 07, 2023 09:00 am ET

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients with recurrent head and neck...

Jan 26, 2023 09:00 am ET

GeoVax to Present at the 2023 BIO CEO & Investor Conference

Jan 25, 2023 11:00 am ET

GeoVax Receives Notice of Allowance for Zika Vaccine Patent

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance...

Jan 04, 2023 09:00 am ET

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st...

Dec 20, 2022 09:00 am ET

Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School...

Dec 07, 2022 04:00 pm ET

GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it has appointed Jayne Morgan, M.D., to its Board of Directors....

Nov 28, 2022 10:15 am ET

GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will...

Nov 09, 2022 04:00 pm ET

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022....

Oct 26, 2022 09:00 am ET

GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after...

Oct 11, 2022 09:00 am ET

GeoVax to Present at Vaccines Summit-2022

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that Senior Scientist Sreenivasa Oruganti, Ph.D., will present at the Vaccines...

Oct 06, 2022 09:00 am ET

GeoVax to Present at Upcoming Investor Conferences

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the Midcap Rodeo: Windy City...

Sep 07, 2022 09:00 am ET

GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 01, 2022 09:00 am ET

GeoVax Announces Addition to Its Board of Directors

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it has appointed Nicole Lemerond, CFA, to its Board of...

Aug 03, 2022 04:00 pm ET

GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the quarter ended June 30, 2022. GeoVax’s...

Jul 28, 2022 09:00 am ET

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

Jul 26, 2022 09:00 am ET

GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report second quarter 2022 financial results on Wednesday,...

Jun 13, 2022 09:00 am ET

GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of John W. Sharkey, PhD to serve as Vice President, Business...

Jun 07, 2022 09:00 am ET

GeoVax to Present at BIO International Convention 2022

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the BIO International...

May 25, 2022 01:47 pm ET

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused...

May 24, 2022 09:00 am ET

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and...

May 04, 2022 09:00 am ET

GeoVax Announces Upcoming Presentations at Scientific Conferences

via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following...

Apr 27, 2022 04:00 pm ET

GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

Apr 26, 2022 09:00 am ET

GeoVax Announces Issuance of Malaria Vaccine Patent

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No....

Apr 19, 2022 09:00 am ET

GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report first quarter 2022 financial results on Wednesday,...

Apr 18, 2022 05:52 pm ET

CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option

via NewMediaWire--In a release issued under the same headline on Monday, April 18th at 1:55 ET by GeoVax, Inc., please note that the release was distributed under the incorrect source and should have been sourced to Aura FAT Projects Acquisition...

Apr 18, 2022 04:05 pm ET

Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option

via NewMediaWire -- Aura FAT Projects Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 10,000,000 units at $10.00 per unit (the “Offering”). Each unit consists of one Class A ordinary share and one...

Apr 12, 2022 09:00 am ET

GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announces today that on April 21, 2022, its Chief Scientific Officer, Mark J. Newman, Ph.D., will...

Mar 22, 2022 09:00 am ET

GeoVax Announces Issuance of Cancer Vaccine Patent

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No....

Mar 21, 2022 09:00 am ET

GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chief Scientific Officer, Mark J. Newman, Ph.D., will deliver a presentation...

Mar 16, 2022 09:00 am ET

GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, has been invited to present at Maxim Group’s 2nd annual Virtual Growth Conference to be...

Mar 14, 2022 09:00 am ET

GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s two ongoing Phase 2 clinical trials...

Mar 10, 2022 09:00 am ET

Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2

via NewMediaWire – A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc. (Nasdaq: GOVX), produced a robust neutralizing antibody and T cell (an immune cell) response against SARS-CoV-2 with no...

Mar 09, 2022 04:00 pm ET

GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2021 and provided an...

Mar 07, 2022 09:00 am ET

GeoVax Announces Key Staff Appointments

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced recent key staff appointments and changes Jeffrey Welch has been appointed to serve...

Feb 23, 2022 09:00 am ET

GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report 2021 financial results on Wednesday, March 9, 2022...

Feb 22, 2022 01:00 pm ET

GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chairman & CEO, David Dodd, has been selected as a 2022 Georgia...

Feb 08, 2022 09:00 am ET

GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present a company overview at the 2022...

Jan 20, 2022 09:00 am ET

GeoVax Announces Closing of $10 Million Private Placement

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced private placement for the issuance and sale...

Jan 14, 2022 08:41 am ET

GeoVax Announces $10 Million Private Placement

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional...

Jan 13, 2022 09:00 am ET

GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s ongoing Phase 1/2 trial, evaluating...

Jan 11, 2022 09:00 am ET

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s...

Jan 05, 2022 09:00 am ET

GeoVax to Participate in Upcoming Life Sciences Investor Conferences

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chairman and CEO, David Dodd, will present at the H.C. Wainwright...

Jan 04, 2022 09:00 am ET

GeoVax Issues Shareholder Update Letter

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today issued an update letter from Chairman and CEO, David Dodd, to the Company’s shareholders and...

Dec 15, 2021 09:00 am ET

GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the initiation of vaccine dosing in the Phase 2 portion of its Phase 1/2 clinical...

Dec 14, 2021 09:00 am ET

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office issued a Notice of...

Dec 03, 2021 09:00 am ET

GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, presented data from ongoing studies of its investigational vaccines against hemorrhagic fevers...

Dec 01, 2021 09:00 am ET

GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chief Scientific Officer, Mark J. Newman, Ph.D., participated in an expert...

Nov 17, 2021 09:00 am ET

GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today presented data from ongoing studies of its preventive vaccine against COVID-19. The...

Nov 16, 2021 09:00 am ET

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

Nov 15, 2021 09:00 am ET

GeoVax Announces Upcoming Presentations at Scientific Conferences

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it will be represented during presentations at the following upcoming...

Nov 11, 2021 04:00 pm ET

GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the quarter ended September 30, 2021 and...

Nov 09, 2021 04:00 pm ET

GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-19 Vaccine

via NewMediaWire -- GeoVax Labs Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has entered into an exclusive license agreement with City of Hope, a...

Nov 04, 2021 09:00 am ET

GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report third quarter 2021...

Oct 18, 2021 09:00 am ET

GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that Mark J. Newman, Ph.D., GeoVax’s Chief Scientific Officer, will participate in an...

Oct 14, 2021 09:00 am ET

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

Sep 28, 2021 04:00 pm ET

GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has entered into an Assignment and License Agreement (the “License”) with...

Sep 07, 2021 09:00 am ET

GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today that Chairman & CEO David Dodd will present at the H.C. Wainwright 23rd Annual Global Investment...

Aug 19, 2021 04:00 pm ET

GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly

GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today...

Aug 12, 2021 09:00 am ET

GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021...

Aug 11, 2021 04:00 pm ET

GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update

Aug 04, 2021 09:00 am ET

GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update

Jul 22, 2021 09:00 am ET

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines, today announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV). The...

Jul 07, 2021 09:00 am ET

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office...

Jun 10, 2021 11:00 am ET

GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that it will be participating in the Alliance Global Partners’...

Jun 07, 2021 09:00 am ET

GeoVax to Present at 2021 BIO Digital

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that it has been selected to deliver a company presentation at 2021...

May 06, 2021 04:00 pm ET

GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the three months ended March 31, 2021....

May 06, 2021 11:30 am ET

GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that management will participate at the Benzinga Global Small Cap...

Apr 26, 2021 09:00 am ET

GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report first quarter 2021...

Apr 01, 2021 09:00 am ET

GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark...

Mar 23, 2021 04:30 pm ET

GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2020....

Mar 17, 2021 09:00 am ET

GeoVax to Participate in Benzinga Biotech Small Cap Conference

via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announces that it will present at the Benzinga Biotech...

Mar 15, 2021 09:00 am ET

GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it plans to report 2020 financial results on Tuesday, March...

Mar 10, 2021 09:00 am ET

GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, has been invited to present at Maxim Group’s Inaugural Emerging Growth Virtual...

Mar 04, 2021 09:55 am ET

GeoVax Expands and Strengthens Intellectual Property Portfolio

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the filing of two additional patent...

Mar 03, 2021 09:00 am ET

GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference

via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President, and CEO David Dodd will present at the H.C....

Mar 01, 2021 09:00 am ET

Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021

Feb 11, 2021 02:00 pm ET

GeoVax Announces Closing of $10.3 Million Bought Deal Offering

Feb 08, 2021 11:43 pm ET

GeoVax Announces Pricing of $9.0 Million Bought Deal Offering

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that it has entered into an underwriting...

Jan 11, 2021 09:00 am ET

Ad blocking detected

GeoVax Labs, Inc. - Warrants (OQ:GOVXW)

Business Focus: N/A